Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Exclusion Criteria

• •Stage Ⅳ (metastatic) breast cancer or bilateral breast cancer;
• •Inflammatory breast cancer;
• •Has received prior any anti-tumor therapy within the past 12 months prior to signing informed consent, including chemotherapy, targeted therapy, radiation therapy, immunotherapy, biotherapy and TACE;
• •Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death - ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \[CTLA-4\];
• •Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer;
• •Major surgical procedure within 4 weeks prior to initiation of study treatment;
• •Active or history of autoimmune disease or immune deficiency diseases except history of autoimmune-related hypothyroidism, controlled Type 1 diabetes mellitus;
• •Has a history of (non-infectious) pneumonitis, interstitial lung disease or uncontrollable systematicness diseases;
• •Administration of a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study;
• •Has a known history of Human Immunodeficiency Virus (HIV);
• •Has known active Hepatitis B, Hepatitis C or Autoimmune hepatitis;
• •Severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia;
• •Has active infection (CTCAE≥2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment;
• •Has evidence of active tuberculosis within 1year prior to initiation of study treatment;
• •Prior allogeneic stem cell or solid organ transplantation;
• •Pre-existing motor or sensory neuropathy of a severity≥grade 2;
• •Has significant cardiovascular disease;
• •Has a known hypersensitivity to the components of the study treatment or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins;
• •Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial;
• •History of neurological or psychiatric disorders, including epilepsy or dementia;
• •Any other situation evaluated by researchers.